Canada Markets open in 9 hrs 14 mins

GeoVax Labs, Inc. (GOVX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.7700-0.3600 (-11.50%)
At close: 04:00PM EST
2.7500 -0.02 (-0.72%)
After hours: 04:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close3.1300
Open2.8800
Bid2.7500 x 900
Ask2.8400 x 900
Day's Range2.6400 - 2.9800
52 Week Range2.6400 - 8.7100
Volume333,649
Avg. Volume1,010,347
Market Cap17.677M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-1.1290
Earnings DateMar. 21, 2022 - Mar. 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    GeoVax Announces $10 Million Private Placement

    Atlanta, GA, Jan. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase

  • GlobeNewswire

    GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial

    Activities Underway to Expand and Accelerate Enrollment of Ongoing Study for Head and Neck Cancer ATLANTA, GA, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of CATO SMS to manage GeoVax’s ongoing Phase 1/2 trial, evaluating the safety and efficacy of repeat cycles of Gedeptin® therapy in patients with recurrent head and neck squamo

  • GlobeNewswire

    GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

    Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Company’s Chief Medical Officer (CMO). Dr. McKee brings over 30 years of experience in research and development, with specific expertise in vaccines, emerging diseases, biodefense, and respiratory viral infections. His